Between January 1, 2016 and July 31, 2021, 28 adult patients [median age: 32 (17–70) years] with r/r Burkitt lymphoma were enrolled in two clinical trials conducted by our department—CD19/CD22 CAR T cell immunotherapy (trial A, n = 15) and CD19/CD22 CAR T cell immunotherapy combined with ASCT (trial B, n = 13). The gene discussed is CD22; the disease is Burkitt lymphoma.